



CLAIMS


1. A therapeutic agent for schizophrenia, which comprises, as an active ingredient, a compound of the formula (I)




5 wherein R^1 is a C_2 - C_6 alkyl group or the formula (II)




wherein R^2 is a hydrogen atom or an acetyl group and R^3 is a C_1 - C_6 alkyl group, a cycloalkyl group or



10 wherein R^4 and R^5 are each independently a hydrogen atom or a C_1 - C_6 alkyl group, and in





of the formula (II), R^2 and R^3 may be linked to each other to form




15

wherein R^6 is a hydrogen atom or a C_1 - C_6 alkyl group;




wherein R^7 and R^8 are each independently a hydrogen atom or a C_1 - C_4 alkyl group,




5

wherein R^9 and R^{10} are each independently a hydrogen atom or a C_1 - C_4 alkyl group,



10 wherein R^{11} is a hydrogen atom or a C_1 - C_4 alkyl group; and




wherein R^{12} and R^{13} are each independently a C_1 - C_4 alkyl group or may be linked to each other to form




15


wherein n is an integer of 2 to 6, or



wherein m is an integer of 2 or 3,



wherein R^{14} is a hydrogen atom or a C_1 - C_4 alkyl group,




5


wherein R^{15} is a hydrogen atom or an aralkyl group, or



provided that when




10




and R^7 should not be a hydrogen atom, an enantiomer thereof, an acid addition salt thereof, or a hydrate or solvate thereof.


2. The therapeutic agent of claim 1, wherein the compound of
15 the formula (I) is a compound of the formula (Ia)




wherein $\text{R}^{1'}$ is a $\text{C}_2\text{-C}_6$ alkyl group or the formula (II)',




wherein R^2 is a hydrogen atom or an acetyl group, and $\text{R}^{3'}$ is a
 5 $\text{C}_1\text{-C}_6$ alkyl group or





wherein R^4 and R^5 are each independently a hydrogen atom or a
 $\text{C}_1\text{-C}_6$ alkyl group, and in



10 of the formula (II)', R^2 and $\text{R}^{3'}$ may be linked to each other to form




wherein R^6 is a hydrogen atom or a $\text{C}_1\text{-C}_6$ alkyl group;
 $\text{R}^{9'}$ and $\text{R}^{10'}$ are each independently a $\text{C}_1\text{-C}_4$ alkyl group; and




wherein R^{15} is an aralkyl group, or




- 5 3. The therapeutic agent of claim 1, wherein the compound of the formula (I) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)



wherein R^{16} is a C_2 - C_6 alkyl group,



or



10

wherein R^6 is a hydrogen atom or a C_1 - C_6 alkyl group; and R^9 and R^{10} are each independently a hydrogen atom or a C_1 - C_4 alkyl group.

- 15 4. The therapeutic agent of claim 1, wherein the compound of the formula (I) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

5. The therapeutic agent of any of claims 1-4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

5